格隆汇2月12日丨福安药业(300194.SZ)公布，全资子公司福安药业集团庆余堂制药有限公司、福安药业 集团宁波天衡制药有限公司、福安药业集团烟台只楚药业有限公司、福安药业集团湖北人民制药有限公 司于近日参与了国家组织集采药品1-8批协议期满品种接续采购的投标工作，根据国家组织集采药品协 议期满品种接续采购办公室（简称"接续采购办公室"）于2026年2月10日发布的《国家组织集采药品协 议期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》显示，公司子公司共计28个药品品种拟中选 本次接续采购。 ...

| 5 | 氨溴索注射剂 | 2ml:15mg | 适用于伴有痰液分泌不正常及排痰功能不良的急性、慢性肺部疾 | | --- | --- | --- | --- | | | | | 病、手术后肺部并发症的预防性治疗。早产儿及新生儿的婴儿呼吸 | | | | 4ml:30mg | 窘迫综合症（IRDS）的治疗。 | | 6 | 多索茶碱注射剂 | 10ml:0.1g | 支气管哮喘、慢性喘息性支气管炎及其他支气管痉挛引起的呼吸困 | | | | | 难。 | | 7 | 左氧氟沙星口服常释剂 | 0.5g | 可用于治疗成年人（≥18 岁）由细菌的敏感菌株所引起的轻、中、 | | | 型 | | 重度感染。 | | 8 | 埃索美拉唑注射剂 | 40mg | 作为当口服疗法不适用时，胃食管反流病的替代疗法、急性胃或十 二指肠溃疡出血的低危患者、用于降低成人胃和十二指肠溃疡出血 | | | | | 内镜治疗后再出血风险。 | | 9 | 碘海醇注射剂 | 100ml：35g（I） | X 线造影剂。可用于心血管造影、动脉造影、尿路造影、静脉造影、 增强检查；颈、胸和腰段椎管造影、经椎管蛛网膜下腔注射后 CT | ...

Group 1 - The core viewpoint of the article indicates that the stock price fluctuations of Fu'an Pharmaceutical (300194) are influenced by multiple factors including macroeconomic environment, industry policies, and market sentiment [1] - In 2025, the company's performance is expected to decline due to industry policy impacts, and the company has released a performance forecast for 2025 through designated media [1] - The company plans to continue optimizing its management and operations to enhance corporate value and shareholder returns [1]

Core Viewpoint - The company acknowledges the significant lag of its stock price compared to the market and attributes this to various factors including macroeconomic conditions, industry policies, and market sentiment [2] Group 1: Company Response - The company expresses gratitude for investor support and addresses concerns regarding stock price performance [2] - The company indicates that it has not considered share buybacks due to the influence of industry policies on its performance, particularly noting a projected decline in 2025 [2] - The company commits to optimizing management and operations to enhance corporate value and shareholder returns in the future [2]

Group 1 - On February 3, Fu'an Pharmaceutical's stock increased by 1.37%, with a trading volume of 59.77 million yuan [1] - The financing data on the same day showed a financing purchase amount of 6.72 million yuan and a financing repayment of 8.12 million yuan, resulting in a net financing buy of -1.40 million yuan [1] - As of February 3, the total balance of margin trading for Fu'an Pharmaceutical was 360 million yuan, which is 6.83% of its circulating market value, indicating a low level compared to the past year [1] Group 2 - As of January 30, the number of shareholders for Fu'an Pharmaceutical was 39,100, an increase of 0.54% from the previous period, while the average circulating shares per person decreased by 0.53% to 24,795 shares [2] - For the period from January to September 2025, Fu'an Pharmaceutical reported an operating income of 1.315 billion yuan, a year-on-year decrease of 34.08%, and a net profit attributable to shareholders of 166 million yuan, down 44.87% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 688 million yuan in dividends, with 202 million yuan distributed in the last three years [2]

Group 1 - The core point of the article is that Fu'an Pharmaceutical reported its shareholder count as of January 30, with a total of 39,053 shareholders [2]

Core Viewpoint - Fu'an Pharmaceutical (300194) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 64.26% to 74.99% compared to the previous year [1] Financial Performance - The company anticipates a net profit of between 70 million to 100 million yuan for 2025 [1] - The net profit, excluding non-recurring gains and losses, is projected to be between 52 million to 78 million yuan, reflecting a decrease of 69.83% to 79.88% year-on-year [1]

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the drug Cefotolan Pivoxil Tablets, which is indicated for various infections caused by sensitive bacteria [1]. Group 1 - The drug Cefotolan Pivoxil Tablets is suitable for treating infections such as folliculitis, infectious pustulosis, subcutaneous abscess, hidradenitis, pharyngitis, acute and chronic bronchitis, tonsillitis, otitis media, sinusitis, and periodontitis [1].

Core Viewpoint - The company, Fu'an Pharmaceutical, anticipates a significant decline in net profit for the fiscal year 2025, projecting a range of 70 million to 100 million yuan, which represents a year-on-year decrease of 64.26% to 74.99% due to the implementation of national drug procurement policies leading to substantial price reductions of its main products [1] Financial Performance - The expected net profit for 2025 is estimated to be between 70 million and 100 million yuan [1] - This projection indicates a decline of 64.26% to 74.99% compared to the previous year [1] Market Conditions - The implementation of national drug procurement is causing a significant drop in sales prices of the company's main products [1] - As a result, the company's operating revenue is decreasing, leading to continued pressure on profit margins [1]

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the drug Cefotolan Pivoxil Tablets, which is indicated for various infections caused by sensitive bacteria [1]. Group 1 - The drug Cefotolan Pivoxil Tablets is suitable for treating infections such as folliculitis, infectious pustulosis, subcutaneous abscess, hidradenitis, pharyngitis, acute and chronic bronchitis, tonsillitis, otitis media, sinusitis, and periodontitis [1].